Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti-interleukin-1beta monoclonal antibody. METHODS: We performed a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS. In part 1, 35 patients received 150 mg of canakinumab subcutaneously. Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 weeks for up to 24 weeks. After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab. We evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA). RESULTS: In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab. Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission. Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P<0.001). At the end of part 2, median CRP and SAA values were normal (<10 mg per liter for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P<0.001 and P=0.002, respectively). Of the 31 patients, 28 (90%) completed part 3 in remission. In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo. CONCLUSIONS: Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, IL-1RA-blocking Ab (anakinra) and IL-1β-blocking Ab (canakinumab) are already FDA approved as anti-inflammatory biologics for the treatment of rheumatoid arthritis (130) and NLRP3-inflammasome-mediated cryopyrin-associated periodic syndrome (CAPS) (131), respectively.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [131]
Citations
Cites
Natural History and Outcome in Systemic AA Amyloidosis
Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,032
Self-citationSpectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. F. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 744
Self-citationHoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577 · cited 2×
“Viral infection 0 2 (13) 0 0 Headache 0 2 (13) 0 3 ( 10 )”
URTICARIA, DEAFNESS, AND AMYLOIDOSIS: A NEW HEREDO-FAMILIAL SYNDROME
(1962) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a066967 · Cited by 372
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Self-citationPrimer: inflammasomes and interleukin 1β in inflammatory disorders
Church, L. D., Cook, G. P., & McDermott, M. F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0681 · Cited by 309
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Bijlsma, J. W. J., Dougados, M., Emery, P., Keystone, E. C., Klareskog, L., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044941 · Cited by 225
Leslie, K. S., Lachmann, H. J., Bruning, E., McGrath, J. A., Bybee, A., Gallimore, J. R., Roberts, P. F., Woo, P., Grattan, C. E., & Hawkins, P. N. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.12.1591 · Cited by 186 · cited 13×
“Rhinitis 4 (11) 1 (7) 2 (12) 0 Bronchitis 3 (9) 1 ( 7 ) 1 (6) 0”
InfluentialSelf-citationAlten, R., Gram, H., Joosten, L. A., Berg, W. B. V. D., Sieper, J., Wassenberg, S., Burmester, G., van Riel, P., Diaz-Lorente, M., Bruin, G. J., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2438 · Cited by 170
The many worlds of reducing interleukin‐1
Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21107 · Cited by 104
Research works printed but not linked: 5
- Muckle TJ, 1962, Q J Med, 31, 235
- Lachmann HJ, 2008, Clin Exp Rheumatol, 26, 181
- Kuemmerle-Deschner JB, 2008, Clin Exp Rheumatol, 26, 180
- Kummerle-Deschner J, 2008, Ann Rheum Dis, 67, 104
- Maier J, 2008, J Rheumatol, 35, 939
Cited by
Items 501–600 of 869
Systemic JIA as an Autoinflammatory Disease
Takei, S. (2011) · Inflammation and Regeneration · doi:10.2492/inflammregen.31.52 · Cited by 12
Mutations in the IL1RN locus lead to autoinflammation
Gabay, C., & Palmer, G. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.177 · Cited by 11
“Administration of anakinra or other IL-1 inhibitors to patients with CAPS results in rapid resolution of their symptoms and normalization of acute-phase protein levels”
BackgroundThe Role of the Inflammasome in Ventilator-induced Lung Injury
dos Santos, C. C. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0649ed · Cited by 11
Kambe, N., Yamamoto, M., Takemura, K., Kagami, S., Kawahara, Y., Yoshifuji, H., Jo, T., Izawa, K., Nakamizo, S., Inoue, N., et al. (2024) · Allergology International · doi:10.1016/j.alit.2024.10.001 · Cited by 10
Liu, H., Yuan, Y., Tian, W., Luo, T., Xu, Q., Zhu, X., & Chen, R. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03279-4 · Cited by 10
Cutaneous manifestations of systemic autoinflammatory disorders
Bölükbasi, B., & Krause, K. (2015) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2015.05.002 · Cited by 10
Wu, N. Q., Wu, D., Zhao, M., Miao, J., Yu, W., Wang, Y., & Shen, M. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13334 · Cited by 10
Sardar, M., Zia, K., Ashraf, S., Malik, H. N., Jabeen, A., Khan, K. M., & Ul‐Haq, Z. (2022) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2022.107774 · Cited by 11
Hui, A., Johnson, L. B., Greemberg, R., Penney, L. S., & RAMSEY, S. E. (2019) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2019.01.037 · Cited by 10
Cryopyrin‐associated periodic fever syndrome in children: A case‐based review
Gupta, A., Tripathy, S. K., Phulware, R. H., Arava, S. K., & Bagri, N. K. (2019) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13772 · Cited by 10
van der Made, C. I., Hoischen, A., Netea, M. G., & van de Veerdonk, F. L. (2020) · Immunological Reviews · doi:10.1111/imr.12898 · Cited by 11
Regulating against the dysregulation: new treatment options in autoinflammation
Kallinich, T. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0501-9 · Cited by 10
Periodic fever syndrome and autoinflammatory diseases
Dickie, L. J., Savic, S., Aziz, A., Sprakes, M. B., & McDermott, M. (2010) · F1000 Medicine Reports · doi:10.3410/m2-3 · Cited by 11
“A published phase III clinical study demonstrated that canakinumab was effective in CAPS patients, with 34 of 35 patients achieving a complete clinical response within 15 days [6].”
MethodBizzini, B., Drouet, B., Zagury, D., Abitbol, M. M., Burny, A., & Boissier, M. (2010) · Immunotherapy · doi:10.2217/imt.10.16 · Cited by 10
Quartier, P. (2011) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s6696 · Cited by 11
Self-citationElmi, A. A., Wynne, K., Cheng, I. L., Eleftheriou, D., Lachmann, H. J., Hawkins, P. N., & Brogan, P. A. (2019) · Pediatric Rheumatology · doi:10.1186/s12969-019-0335-4 · Cited by 10
Self-citationLiu, H., Yan, W., Li, J., Yan, D., & Luo, D. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1483669 · Cited by 9
Guidelines for the management and treatment of periodic fever syndromes
Terreri, M. T. R. A., Bernardo, W. M., Len, C. A., Silva, C. A., de Magalhães, C. M. R., Sacchetti, S., Ferriani, V. P. L., Piotto, D. G. P., Cavalcanti, A., de Moraes, A. J. P., et al. (2015) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2015.08.020 · Cited by 10
Tapering of biological treatment in autoinflammatory diseases: a scoping review
Welzel, T., Oefelein, L., Twilt, M., Pfister, M., Kuemmerle-Deschner, J. B., & Benseler, S. M. (2022) · Pediatric Rheumatology · doi:10.1186/s12969-022-00725-3 · Cited by 9
“Treatment responses are defined by a composite index of PPGA/PGA plus inflammatory parameters [4, 5].”
BackgroundSelf-citationKoné‐Paut, I., Piram, M., Benseler, S. M., Kuemmerle-Deschner, J. B., Jansson, A. F., Rosner, I., Tommasini, A., Murías, S., Karadağ, Ö., Lévy, J., et al. (2022) · Joint Bone Spine · doi:10.1016/j.jbspin.2022.105448 · Cited by 10
Self-citationHosono, K., Kato, C., & Sasajima, T. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/pjs6eh · Cited by 9
Shimogaki, S., Ito, S., Komatsu, S., Koike, R., Miyasaka, N., Umezawa, K., & Kubota, T. (2013) · Modern Rheumatology · doi:10.3109/14397595.2013.844298 · Cited by 10
Autoinflammatorische Syndrome und Amyloid-A-Amyloidose
Blank, N., & Schönland, S. O. (2020) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-020-00778-3 · Cited by 9
Autoinflammatory Disorders, Pain, and Neural Regulation of Inflammation
Chen, M. C., & Meckfessel, M. (2013) · Dermatologic Clinics · doi:10.1016/j.det.2013.04.002 · Cited by 9
Nature-inspired IL-1 targeted therapy to treat chronic inflammatory diseases
Yang, Y.-S., Kim, M., Chaugule, S. R., Mayer, E., DeSouza, N. H., Ma, H., Xie, J., Lee, K., Li, S., Gravallese, E. M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.008 · Cited by 9
Cui, J., Yang, M., Yu, C., Zhang, H., Gong, Y., Hu, Y., Wang, Y., Yuan, Q., Pan, A., Li, J.-P., et al. (2025) · Advanced Science · doi:10.1002/advs.202411355 · Cited by 9
Mueller, S. M., Itin, P. H., & Haeusermann, P. (2011) · Dermatology · doi:10.1159/000331580 · Cited by 8
AA-amyloidosis in autoinflammatory diseases
Рамеев, В. В., Moiseev, S. V., & Lysenko, L. V. (2021) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2021-4-52-61 · Cited by 8
Negi, K., Agarwal, M., Pahuja, I., Bhardwaj, B., Rawat, M., Bhaskar, A., & Dwivedi, V. P. (2023) · Oxford Open Immunology · doi:10.1093/oxfimm/iqad001 · Cited by 9
“Hence, it can proficiently obstruct pro-inflammatory response of both subtypes IL-1a and IL-1b by competitively inhibiting IL-1 from binding to IL-1 type I receptor.”
InfluentialBiologic modulators in allergic and autoinflammatory diseases
Broderick, L., Tourangeau, L. M., Kavanaugh, A., & Wasserman, S. I. (2011) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e328348a882 · Cited by 8
Watanabe, M., Nishikomori, R., Fujimaki, Y., Heike, T., Ohara, A., & Saji, T. (2017) · Clinical Case Reports · doi:10.1002/ccr3.1149 · Cited by 8
Cryopyrin-Associated Periodic Syndromes (CAPS)
Hoffman, H. M., Kuemmerle-Deschner, J. B., & Goldbach‐Mansky, R. T. (2019) · Springer eBooks · doi:10.1007/978-3-319-98605-0_19 · Cited by 10
Self-citationCryopyrin-associated periodic syndrome presenting with posterior scleritis
Alvarez, E. R., Corless, B., Kontzias, A., & Cebulla, C. M. (2019) · Rheumatology · doi:10.1093/rheumatology/kez197 · Cited by 8
Urticaria inducible: serie de casos y revisión de la literatura
Amaya, D., Sánchez, A., & Sánchez, J. (2015) · Biomédica · doi:10.7705/biomedica.v36i1.2678 · Cited by 12
Empfehlungen zur Therapie mit Interleukin-1β-blockierenden Wirkstoffen
der DGRh, K. P., Manger, B., Gaubitz, M., & Michels, H. (2009) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-009-0542-3 · Cited by 8
“1), berücksichtigt [54].”
BackgroundSalugina, S. O., Fedorov, E. S., & Kuzmina, N. N. (2016) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2016-2-4-11 · Cited by 8
The First Case Series of Cryopyrin-Associated Periodic Syndrome in Korea
Han, J. H., Je, Y., Yoon, H. J., Ahn, J. G., Lee, J., Park, J., & Park, H. J. (2019) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2019.11.4.583 · Cited by 8
Current and Potential Biologic Drugs for the Treatment of Chronic Urticaria
Sánchez‐Borges, M., Díaz, S. N. G., Ortega‐Martell, J. A., Rojo, M. I., & Ansotegui, I. J. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2020.06.005 · Cited by 8
Syndrome périodique lié à la cryopyrine : CAPS vu à l’âge adulte
Koné‐Paut, I. (2015) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2014.10.006 · Cited by 8
Undifferentiated autoinflammatory disease in adults: a prospective study in 61 patients
Miao, J., Wu, D., & Shen, M. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03685-5 · Cited by 7
A Glance at History and Future Perspectives of Childhood Autoinflammatory Disorders
Polat, A., Demirkaya, E., Başbozkurt, G., Gattorno, M., Özen, S., & FAVOR, F. (2012) · Annals of Paediatric Rheumatology · doi:10.5455/apr.022120120023 · Cited by 7
“A randomized withdrawal study exhibited that 97% of the patients responded to treatment and 81% patients demonstrated disease flare due to withdrawal of the drug [39].”
BackgroundTreatment of systemic-onset juvenile arthritis with canakinumab
Horneff, G., & Peitz, J. (2015) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s54215 · Cited by 7
Assady, S., Ramadan, R., & Rubinger, D. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10080-6 · Cited by 7
Yamasaki, Y., Kubota, T., Takei, S., Imanaka, H., Nonaka, Y., & Kawano, Y. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05267-1 · Cited by 7
Cutaneous signs and mechanisms of inflammasomopathies
Borst, C., Symmank, D., Drach, M. C., & Weninger, W. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220977 · Cited by 8
Drugs for paediatric hyperinflammatory syndromes
Hon, K. E., Leung, A. K. C., Leung, W. H., Leung, K. K. Y., Cheong, K. N., & Lee, P. P. (2022) · Drugs in Context · doi:10.7573/dic.2022-2-1 · Cited by 7
Bonnekoh, H., Butze, M., Spittler, S., Staubach, P., Weller, K., Scheffel, J., Maurer, M., & Krause, K. (2023) · Clinical and Translational Allergy · doi:10.1002/clt2.12226 · Cited by 8
Gedik, K. C., Ortega‐Villa, A. M., Materne, G., Rastegar, A. T., Sanchez, G. A. M., Reinhardt, A., Brogan, P. A., Berkun, Y., Murías, S., Robles, M., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-225463 · Cited by 8
Updates in the Diagnosis and Treatment of Vasculitis
Sakkas, L. I., & Katsiari, C. G. (2013) · InTech eBooks · doi:10.5772/46068 · Cited by 8
Eczema and Urticaria as Manifestations of Undiagnosed and Rare Diseases
Youssef, M. J., & Chiu, Y. E. (2016) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2016.08.004 · Cited by 7
Interleukin-1 Mediated Autoinflammation from Heart Disease to Cancer
Dinarello, C. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-98605-0_39 · Cited by 8
Mori, T., Saburi, M., Hagihara, M., Mori, M., Yamazaki, R., & Kato, J. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218695 · Cited by 7
Etiopatogenia de los síndromes asociados a criopirina: genética, bases moleculares y el inflamasoma
Aróstegui, J. I. (2011) · Medicina Clínica · doi:10.1016/s0025-7753(11)70005-7 · Cited by 7
Diagnostic validity of colchicine in patients with Familial Mediterranean fever
Özaltın, F., Bilginer, Y., Gülhan, B., Bajin, İ. Y., Erdoğan, Ö., Hayran, M., Yılmaz, E., & Özen, S. (2014) · Clinical Rheumatology · doi:10.1007/s10067-014-2598-y · Cited by 8
Kortus-Götze, B., & Hoyer, J. D. (2011) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfr118 · Cited by 7
“[8] reported about the successful treatment with canakinumab once every 8 weeks in patients with CAPS.”
BackgroundImmune Compromise Associated with Biologics
Eisenberg, R. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405546-9.00049-2 · Cited by 8
Ilowite, N. T., & Laxer, R. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24145-8.00013-2 · Cited by 8
The systemic autoinflammatory disorders for dermatologists. Part 2: disease examples
Oldham, J., & Lachmann, H. J. (2020) · Clinical and Experimental Dermatology · doi:10.1111/ced.14251 · Cited by 8
Self-citationProlonged, Recurrent, and Periodic Fever Syndromes
Long, S. S., & Edwards, K. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-7020-3468-8.50023-7 · Cited by 7
Argentieri, M., Boncompagni, C., Sturaro, C., Pola, P., d'Ugo, C., Frezza, A., Stragapede, S., Pacifico, S., Albanese, V., Preti, D., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118411 · Cited by 6
Innate immunity: current understandings and future perspectives
Zou, C., Ma, T., Li, J., & Zhou, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02920-0 · Cited by 11
The Emerging Specialty of Cardio-Rheumatology
Nayfeh, M., DiGregorio, H. R., Saad, J. M., Al-Mallah, M. H., & Rifai, M. A. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01221-7 · Cited by 9
“Canakinumab, a fully human monoclonal antibody target - ing interleukin-1β is well known for its clinical use in rheu - matological disorders [106, 107].”
Vasculitis, Autoimmunity, and Cytokines: How the Immune System Can Harm the Brain
Tesser, A., Pin, A., Mencaroni, E., Gulino, A. V., & Tommasini, A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18115585 · Cited by 6
Hur, P., Lomax, K. G., Ionescu‐Ittu, R., Manceur, A. M., Xie, J., Cammarota, J., Gautam, R., Sanghera, N., Kim, N., & Grom, A. A. (2021) · Pediatric Rheumatology · doi:10.1186/s12969-021-00605-2 · Cited by 6
“Clinical trials have demonstrated strong efficacy of canakinumab in the treatment of patients with PFS [5, 15].”
BackgroundInfluentialChapelle, N., Fantou, A., Marron, T., Kenigsberg, E., Mérad, M., & Martin, J. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1006944 · Cited by 6
Rußwurm, M., Johannsen, S., Kortus-Götze, B., & Haas, C. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-67380-4 · Cited by 6
“Anti-IL-1 therapy is the gold standard of therapy for CAPS 4 .”
BackgroundBiologic Therapy in the Treatment of Chronic Skin Disorders
Fernandez, J., Fernandez, A. P., & Lang, D. M. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.01.006 · Cited by 8
Autoinflammation: Past, Present, and Future
Kastner, D. L. (2019) · Springer eBooks · doi:10.1007/978-3-319-98605-0_1 · Cited by 8
Novel mutation in the NRLP3 manifesting as an intermediate phenotype of cryopyrinopathies
Paim-Marques, L., Cavalcante, A. V., Castro, C., Muskardin, T. W., Oliveira, J. B., Niewold, T. B., & Appenzeller, S. (2020) · Rheumatology International · doi:10.1007/s00296-020-04683-5 · Cited by 6
Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis
Bender, T. T. A., Leyens, J., Sellin, J., Kravchenko, D., Conrad, R., Mücke, M., & Seidel, M. F. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01576-5 · Cited by 6
Goksøyr, L., Funch, A. B., Okholm, A. K., Theander, T. G., de Jongh, W. A., Bonefeld, C. M., & Sander, A. F. (2022) · Vaccines · doi:10.3390/vaccines10050828 · Cited by 7
Sleptsova, T. V., Alexeeva, E. I., Savostyanov, K. V., Pushkov, A. A., Nikitin, A. G., Bzarova, T. M., Valieva, S. I., Fetisova, A. N., Pakhomov, A. V., Zhurkova, N. V., et al. (2014) · Вопросы современной педиатрии · doi:10.15690/vsp.v13i3.1035 · Cited by 6
Kälteinduzierte Quaddeln und Angioödeme: Klassifikation, Diagnostik und Therapie
Krause, K., Degener, F., Altrichter, S., Ardelean, E., Kalogeromitros, D. C., Magerl, M. A. K., Metz, M., Siebenhaar, F., Weller, K., & Maurer, M. (2010) · Der Hautarzt · doi:10.1007/s00105-010-1932-9 · Cited by 12
Accelerate medical breakthroughs by ending disease earmarks
Terry, S. F. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2782 · Cited by 6
“Two pharmaceutical companies (Regeneron and Novartis) have recently done just that by developing drugs for a very rare genetic condition known as cryopyrin-associated periodic syndrome (CAPS”
BackgroundCanakinumab for the treatment of systemic juvenile idiopathic arthritis
Grom, A. A. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.965149 · Cited by 6
Yokota, S., Kikuchi, M., Nozawa, T., KIZAWA, T., Kanetaka, T., Miyamae, T., Mori, M., Nishikomori, R., TAKATA, H., Heike, T., et al. (2012) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.35.23 · Cited by 6
Pharmacological Properties of Monoclonal Antibodies Directed Against Interleukins
Georgiev, K., & Georgieva, M. (2015) · InTech eBooks · doi:10.5772/61774 · Cited by 6
Actualités sur l’inhibition de l’interleukine-1
de BOYSSON, H. (2012) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.01.012 · Cited by 6
Hereditary Periodic Fever Syndromes
Gedalia, A. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00157-3 · Cited by 6
Online home self-assessment: A tool for improving future treatment trials?
Berthelot, J., Batard, K., Goff, B. L., & Maugars, Y. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.10.005 · Cited by 6
Target practice: Opportunities for therapeutic intervention in CHIP and CCUS
Mohammad, A., Mascarenhas, J. O., Marcellino, B. K., & Nathan, D. I. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101323 · Cited by 5
Terreri, M. T. R. A., Bernardo, W. M., Len, C. A., Silva, C. A., de Magalhães, C. M. R., Sacchetti, S., Ferriani, V. P. L., Piotto, D. G. P., Cavalcanti, A., de Moraes, A. J. P., et al. (2015) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2015.08.007 · Cited by 8
Investigational drugs in systemic vasculitis
Mirouse, A., Cacoub, P., Desbois, A. C., Comarmond, C., Pagnoux, C., & Saadoun, D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1361928 · Cited by 5
Muckle–Wells Cryopyrinopathy: Complex Phenotyping and Response to Therapy in a New Multiplex Kindred
Headley, A. P., Cordingley, F. T., Hawkins, P. N., & Riminton, S. (2013) · Inflammation · doi:10.1007/s10753-013-9752-6 · Cited by 6
Self-citationTargeting cytokines in inflammatory diseases: focus on interleukin-1-mediated autoinflammation
Kalliolias, G. D., & Ivashkiv, L. B. (2009) · F1000 Biology Reports · doi:10.3410/b1-70 · Cited by 5
Clinical and Molecular Genetic Features of Autoinflammatory Syndromes in Children
Alexeeva, E. I., Savostyanov, K. V., Sleptsova, T. V., Pushkov, A., Valieva, S. I., Bzarova, T. M., Isaeva, K. B., Chistyakova, Е. G., Chomakhidze, А. М., Denisova, R. V., et al. (2015) · Вопросы современной педиатрии · doi:10.15690/vsp.v14i3.1372 · Cited by 5
Koné‐Paut, I., & Dusser, P. (2020) · Giornale Italiano di Dermatologia e Venereologia · doi:10.23736/s0392-0488.20.06708-5 · Cited by 6
Endo, K., Suzuki, A., Sato, K., & Shiga, T. (2015) · BMJ Case Reports · doi:10.1136/bcr-2015-209468 · Cited by 5
Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease
Mehta, J., & Beukelman, T. (2017) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2017.06.041 · Cited by 5
Salugina, S. O., Fedorov, E. S., Kuzmina, N. N., & Zakharova, E. Y. (2014) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2014-4-17-24 · Cited by 5
Milchert, M., Makowska, J. S., Brzezińska, O. E., Brzosko, M., & Więsik–Szewczyk, E. (2019) · Reumatologia/Rheumatology · doi:10.5114/reum.2019.91298 · Cited by 5
“All preparations effectively relieve clinical symptoms, which is accompanied by the normalization of laboratory inflammatory markers, and prevent the development of amyloidosis [54, 55].”
BackgroundMakoni, M. M., & Mukundan, D. (2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3283350f95 · Cited by 5
Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review
Joshi, T. P., Wang, H. Y., Athukuri, P., Bohac, S., Farr, M. A., Hinson, D., Kahla, J. A., Khalfe, N., McBee, D. B., Stroh, R., et al. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00700-4 · Cited by 5
“In 2009, two studies found canakinumab to be effective in treating cryopyrinopathies, with one randomized controlled trial demonstrating a complete response in 97% (34/35) of patients [29], and a prospective study reporting a complete response in 100% (4/4) of patients within 1 week of therapy [30].”
BackgroundRationale for IL-1β-targeted therapy to minimize hypoxic-ischemic encephalopathy
Wanderer, A. A. (2009) · Journal of Perinatology · doi:10.1038/jp.2009.114 · Cited by 5
Gene engineering biological therapy for juvenile arthritis
Михельс, Х., Никишина, И. П., Федоров, Е. С., Salugina, S. O., Michels, H., Никишина, И. П., Федоров, Е. С., & Salugina, S. O. (2011) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2011-873 · Cited by 6
Cold-induced urticaria with a familial transmission: a case report and review of the literature
Furr, J. C., & Panda, M. (2012) · Journal of Medical Case Reports · doi:10.1186/1752-1947-6-70 · Cited by 6
“Canakinumab was well tolerated and caused few injection site reactions, although the incidence of suspected infection was higher versus placebo [15].”
BackgroundHereditary Disorders Presenting with Urticaria
Kanazawa, N. (2013) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2013.08.001 · Cited by 6
The autoinflammatory diseases: a fashion with blurred boundaries!
Sarrabay, G., Barat‐Houari, M., Annakib, S., & Touitou, I. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0495-3 · Cited by 5
Principles of Systemic Therapy
Tidman, M. J., & Smith, C. H. (2016) · Wiley eBooks · doi:10.1002/9781118441213.rtd0019 · Cited by 6
T cells in cardiovascular disease: solved and unsolved mysteries
Hou, Y., Gao, W., Zhou, B., & Lui, K. O. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2976-8 · Cited by 4
“Recently, a human anti-IL-1 β monoclonal antibody, canakinu-mab, has been approved for clinical use in inflammatory diseases (Lachmann et al., 2009; Ruperto et al., 2012).”
Metadata
- Authors
- Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N.
- Affiliations
- University College London (GB)
- Universitätsklinikum Tübingen (DE)
- University of California, San Francisco (US)
- Université de Lille (FR)
- Hôpital Necker-Enfants Malades (FR)
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-06-04
- Volume
- 360
- Issue
- 23
- Pages
- 2416-2425
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149374693
- Cited by
- 869
- References
- 19
- Citations by year
- 2026: 23 · 2025: 30 · 2024: 31 · 2023: 23 · 2022: 37 · 2021: 40 · 2020: 53 · 2019: 56 · 2018: 34 · 2017: 38 · 2016: 55 · 2015: 67 · 2014: 50 · 2013: 66 · 2012: 73
- FWCI
- 35.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- canakinumab, cryopyrin-associated periodic syndromes, IL-1β, interleukin-1 receptor antagonist, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, disease flares, C-reactive protein, serum amyloid A, infection risk, urosepsis, vertigo, treatment withdrawal
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Adolescent, Adult, Aged, Antibodies, Monoclonal, Carrier Proteins, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Familial Mediterranean Fever, Interleukin-1beta, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.